Laura Towart: Vivan Therapeutics Selected for the Unrest Impact Investor Cohort
Laura Towart, Founder and CEO at Vivan Therapeutics, shared a post on LinkedIn: “Delighted that Vivan Therapeutics has been selected by Unrest for the current Impact Investor Cohort. Unrest has […]
Read the full articleYou might also wanna read
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
The company recently wowed investors with clinical trial results.
Fierce Biotech Fundraising Tracker '26: Celea raises $180M for phase 3 study of PureTech IPF drug
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.
Forte Biosciences' FB102 shows efficacy in vitiligo Phase 1b study
See the rest of the story here . thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The F
Bio Usawa appoints former Pfizer chief medical officer Dr. Aida Habtezion to board of directors
KIGALI, Rwanda and SAN FRANCISCO, June 15, 2026 (GLOBE NEWSWIRE) — Bio Usawa, a biotechnology company dedicated to expanding access to high-
financialpost.com·25d agoAtlan Is Part of the Third Batch of Surge by Sequoia Capital
Our week just got off to a brilliant start as we joined the third batch of Surge, a program by Sequoia Capital for rapidly scaling startups.
Nura raises $73.8M to target ALS through a unique target
Biospace reports that Nura Bio has raised $73.8 million in financing to carry two neuroprotective drug candidates through early to mid-stage
Comments
Sign in to join the conversation.
No comments yet. Be the first.